Alpine Immune Sciences

Leading the Next Evolution of Immunotherapies


Alpine Immune Sciences

Novel proteins created using directed evolution-based discovery platform


Alpine Immune Sciences

Helping patients with cancer and autoimmune disease


Leading the Next Evolution of Immunotherapies

We create protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory disorders.

Alpine Immune Sciences capitalizes on our unique understanding of the immune synapse, using our directed evolution platform to engineer native immune system proteins for therapeutic benefit.

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

  • Completion of Phase 1 Study for Lead Autoimmune/Inflammatory Disease Program, ALPN-101
  • BALANCE Trial of ALPN-101 in Acute GVHD Open for Enrollment
  • NEON-1 Trial of ALPN-202 in Advanced Malignancies Open for Enrollment
  • Orphan Drug Designations by the U.S. FDA for ALPN-101 for the Treatment and Prevention of Acute GVHD
Read More

At Alpine Immune Sciences, we are applying our platform discovery technology to bring innovative new drugs to people living with cancer and autoimmune/inflammatory diseases

Directed Evolution Platform

Alpine’s powerful directed evolution platform is based upon proteins native to the immune synapse, engineering potentially novel “Variant immunoglobulin domains” or “vIgDs”. Our vIgDs can engage multiple targets simultaneously, can be significantly more potent then native proteins, and have the potential improve therapeutic outcomes for the treatment of cancer and autoimmune/inflammatory conditions.

Because vIgDs are based upon natural participants in the immune synapse, they potentially provide a mechanistic advantage over larger, more artificial constructs.

Lead Programs

ALPN-101 is a first-in-class dual CD28/ICOS antagonist being developed for the treatment of autoimmune and inflammatory diseases. A Phase 1 healthy volunteer study has been completed and we anticipate the start of ‘BALANCE’, a Phase 1b/2 clinical trial in GVHD, to begin in 2020.

ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor being developed for the treatment of cancer. We anticipate a Phase 1 trial in cancer patients to begin in 2020.

Our Transmembrane Immunomodulatory Protein (TIP) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL. TIPs are based upon our core vIgD technology, but are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.